A Phase I/II Trial to Evaluate the Safety and Tolerability of Clazakizumab (Anti-IL-6 Monoclonal) As an Agent to Eliminate Donor Specific HLA Antibodies and Improve Outcomes of Patients With Chronic & Active Antibody-Mediated Rejection Post-Kidney Transplantation

Trial Profile

A Phase I/II Trial to Evaluate the Safety and Tolerability of Clazakizumab (Anti-IL-6 Monoclonal) As an Agent to Eliminate Donor Specific HLA Antibodies and Improve Outcomes of Patients With Chronic & Active Antibody-Mediated Rejection Post-Kidney Transplantation

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Jan 2018

At a glance

  • Drugs Clazakizumab (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Dec 2017 Planned initiation date changed from 26 Dec 2017 to 15 Jan 2018.
    • 29 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top